News
12-10-2017, 01:06 AM
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
More... (https://www.news-medical.net/news/20171208/PARP-inhibitor-can-be-new-treatment-option-for-patients-with-metastatic-breast-cancer-BRCA-mutations.aspx)
More... (https://www.news-medical.net/news/20171208/PARP-inhibitor-can-be-new-treatment-option-for-patients-with-metastatic-breast-cancer-BRCA-mutations.aspx)